Albany Molecular Research (AMRI) expects to initiate operations in Singapore in the first quarter of 2005, with the goal of providing a full range of fee-for-service chemistry technologies, including medicinal and combinatorial chemistry, process research and scale up chemistry, analytical services and cGMP manufacture of active pharmaceutical ingredients.
“AMRI’s expansion into Singapore represents the first step in a strategic move to globalize our services platform,” said AMRI chairman, president and CEO Dr Thomas D’Ambra. “As this initiative succeeds, we believe ultimately that a global range of options will lead to an increase in growth for AMRI’s US-based service operations.”
AMRI’s Singapore operations will be overseen by senior vice president of chemistry, Dr Michael Trova, and led in Singapore by assistant director of medicinal chemistry, Dr Polivina Jolicia Gauuan. Three additional scientists from Albany will be relocating to Singapore, and they are actively recruiting with the expectation of hiring new scientists locally in the coming months.
“We are excited to participate in this industrial expansion in Singapore as the first healthcare research company located there with strength in chemistry research and know-how,” concluded D’Ambra.